03:18 PM EDT, 07/24/2026 (MT Newswires) -- Outlook Therapeutics ( OTLK ) said Friday the US Food and Drug Administration has approved Lytenava for the treatment of neovascular age-related macular degeneration, commonly known as wet AMD, which is a chronic, progressive retinal disease.

The company said it expects the approval to grant Lytenava 12 years of reference product exclusivity under the Biologics Price Competition and Innovation Act.

Outlook Therapeutics ( OTLK ) said it is now executing the commercial launch of Lytenava and expects to make the ophthalmic formulation of bevacizumab available to eligible US patients before year-end.

Price: 1.58, Change: +0.26, Percent Change: +19.32